BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM

Fang, Wei; Wu, Yingfen; Tang, Le; He, Yi; Shi, Lei; Xiong, Fang; Gong, Zhaojian; Guo, Can; Li, Xiayu; Liao, Qianjin; Zhang, Wenling; Zhou, Ming; Xiang, Bo; Li, Xiaoling; Li, Yong; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang

doi:10.1038/bjc.2017.385

Cited by 79 publications

(77 citation statements)

References 57 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Malignant tumors are a major threat to human health. Nasopharyngeal carcinoma, oral cancer, thyroid cancer, ovarian cancer, and lung cancer are common malignant tumors that show high rates of metastasis . Moreover, the malignant progression and high mortality rates associated with these tumors are related to their insidious onset, frequent metastasis and recurrence, and poor prognosis .…”

Section: Discussionmentioning

confidence: 99%

“…Nasopharyngeal carcinoma, oral cancer, thyroid cancer, ovarian cancer, and lung cancer are common malignant tumors that show high rates of metastasis. [26][27][28] Moreover, the malignant progression and high mortality rates associated with these tumors are related F I G U R E 2 circMAN1A2 was highly expressed in the sera of patients with oral cancer, thyroid cancer, ovarian cancer, or lung cancer. A-D, Relative expression of circMAN1A2 in oral cancer (A), thyroid cancer (B), ovarian cancer (C), and lung cancer (D).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

et al. 2019

Self Cite

View full text Add to dashboard Cite

Novel diagnostic and prognostic biomarkers of cancers are needed to improve precision medicine. Circular RNAs act as important regulators in cancers at the transcriptional and posttranscriptional levels. The circular RNA circMAN1A2 is highly expressed in nasopharyngeal carcinoma according to our previous RNA sequencing data; however, the expression and functions of circMAN1A2 in cancers are still obscure. Therefore, in this study, we evaluated the expression of circMAN1A2 in the sera of patients with nasopharyngeal carcinoma and other malignant tumors and analyzed its correlations with clinical features and diagnostic values. The expression levels of circMAN1A2 were detected by quantitative real‐time PCR, and the correlations of clinical features with circMAN1A2 expression were analyzed by χ2 tests. Receiver operating characteristic curves were used to evaluate the clinical applications of circMAN1A2. The results showed that circMAN1A2 was upregulated in nasopharyngeal carcinoma, oral cancer, thyroid cancer, ovarian cancer, and lung cancer, with areas under the curves of 0.911, 0.779, 0.734, 0.694, and 0.645, respectively, indicating the good diagnostic value of circMAN1A2. Overall, our findings suggested that circMAN1A2 could be a serum biomarker for malignant tumors, providing important insights into diagnostic approaches for malignant tumors. Further studies are needed to elucidate the mechanisms of circMAN1A2 in the pathogenesis of cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Metastasis of tumors typically leads to patient death [113][114][115][116][117]. Studies have shown that the high expression and amplification of the MYC gene can promote tumor metastasis, which is closely related to the epithelial-mesenchymal transition (EMT) of tumor cells [118,119].…”

Section: Pvt1 Participates In the Downstream Epithelialmesenchymal Trmentioning

confidence: 99%

Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis

Jin

Wang

Zhang

et al. 2019

Cell. Mol. Life Sci.

Self Cite

112

View full text Add to dashboard Cite

Numerous studies have shown that non-coding RNAs play crucial roles in the development and progression of various tumor cells. Plasmacytoma variant translocation 1 (PVT1) mainly encodes a long non-coding RNA (lncRNA) and is located on chromosome 8q24.21, which constitutes a fragile site for genetic aberrations. PVT1 is well-known for its interaction with its neighbor MYC, which is a qualified oncogene that plays a vital role in tumorigenesis. In the past several decades, increasing attention has been paid to the interaction mechanism between PVT1 and MYC, which will benefit the clinical treatment and prognosis of patients. In this review, we summarize the coamplification of PVT1 and MYC in cancer, the positive feedback mechanism, and the latest promoter competition mechanism of PVT1 and MYC, as well as how PVT1 participates in the downstream signaling pathway of c-Myc by regulating key molecules. We also briefly describe the treatment prospects and research directions of PVT1 and MYC.

show abstract

“…The experimental procedures were conducted with reference to the methods in previously published papers [23,24]. Approximately 100 μL of Matrigel was spread on the bottom of a 24 -well plate for 2~4 h at 37°C until the colloid solidified.…”

Section: Three-dimensional Invasion Assaymentioning

confidence: 99%

“…According to statistical methods used in a previous study [24], clonal spheroids were divided into two types based on the cell protrusions: cells with distinct protrusions were considered invasive clonal spheroids, and other cells were considered noninvasive.…”

Section: Three-dimensional Invasion Assaymentioning

confidence: 99%

BRD7 suppresses invasion and metastasis in breast cancer by negatively regulating YB1-induced epithelial-mesenchymal transition

Niu

Luo

Zhou

et al. 2020

J Exp Clin Cancer Res

Self Cite

View full text Add to dashboard Cite

Background: BRD7 is a tumor suppressor known to inhibit cell proliferation and cell cycle progression and initiate apoptosis in breast cancer. However, the function and underlying molecular events of BRD7 in tumor invasion and metastasis in breast cancer are not fully understood.Methods: BRD7 expression was assessed in two stable cell lines MDA231 and MCF7 with BRD7 overexpression and one stable cell line MDA231 with BRD7 interference using qRT-PCR and western blotting. CCK8 assay was used to examine the proliferation ability of MDA231 and MCF7 cells. Scratch wound healing assay was used to evaluate cell migration in MDA231 and MCF7 cells. Both Matrigel and three-dimensional invasion assays were performed to investigate the cell invasion ability after BRD7 overexpression or silencing or YB1 restoration in MDA231 and MCF7 cells. The potential interacting proteins of BRD7 were screened using co-immunoprecipitation combined with mass spectrometry and verified by co-immunoprecipitation in HEK293T cells. Additionally, we confirmed the specific binding region between BRD7 and YB1 in HEK293T cells by constructing a series of deletion mutants of BRD7 and YB1 respectively. Finally, xenograft and metastatic mouse models using MDA231 cells were established to confirm the effect of BRD7 on tumor growth and metastasis.Results: Here, the results of a series of assays in vitro indicated that BRD7 has the ability to inhibit the mobility, migration and invasion of breast cancer cells. In addition, YB1 was identified as a novel interacting protein of BRD7, and BRD7 was found to associate with the C-terminus of YB1 via its N-terminus. BRD7 decreases the expression of YB1 through negatively regulating YB1 phosphorylation at Ser102, thereby promoting its proteasomal degradation. Furthermore, gene set enrichment analysis revealed that epithelial-mesenchymal transition (EMT) is the common change occurring with altered expression of either BRD7 or YB1 and that BRD7 represses mesenchymal genes and activates epithelial genes. Moreover, restoring the expression of YB1 antagonized the inhibitory effect of BRD7 on tumorigenicity, EMT, invasiveness and metastasis through a series of in vitro and in vivo experiments. Additionally, BRD7 expression was negatively correlated with the level of YB1 in breast cancer patients. The combination of low BRD7 and high YB1 expression was significantly associated with poor prognosis, distant metastasis and advanced TNM stage.

show abstract

BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM

Cited by 79 publications

References 57 publications

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis

BRD7 suppresses invasion and metastasis in breast cancer by negatively regulating YB1-induced epithelial-mesenchymal transition

Contact Info

Product

Resources

About